LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the January 3, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of a class (the “Class”) of investors who purchased Allergan PLC (“Allergan” or the “Company”) (NYSE: AGN) securities between February 25, 2014 and November 3, 2016, inclusive (the “Class Period”). Allergan investors have until January 3, 2017 to file a lead plaintiff motion.
On November 3, 2016, Bloomberg News published an article disclosing a years-long investigation by the United States Department of Justice into alleged price fixing by Allergan and other generic drug producers.
According to the Complaint filed in this securities class action lawsuit, Allergan made false and/or misleading statements and/or failed to disclose that: the Company and Actavis (an Allergan subsidiary) engaged in conduct that would result in a Department of Justice (“DOJ”) antitrust investigation; that the DOJ investigation and the underlying conduct could cause U.S. prosecutors to file criminal charges against the Company by the end of 2016 for suspected price collusion; that Allergan and Actavis lacked effective internal controls; and that as a result of the above, Allergan’s and Actavis’ public statements were materially false and misleading at all relevant times.
Note: On December 14, 2016, the United States Justice Department accused two Heritage Pharmaceuticals, Inc. executives of colluding with other generic pharmaceutical companies to fix prices, the first criminal charges stemming from a sweeping criminal investigation into alleged price fixing by over a dozen generic drug companies.
If you purchased Allergan shares, you may move the Court no later than January 3, 2017 to request appointment as lead plaintiff. To be a member of the class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to email@example.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.